Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806243 | 0.83 | ERN1 (0.43) | ERN1CYP11B2CHRM1USP30GSK3B | |
| SCHEMBL17809538 | 0.77 | ERN1 (0.47) | ERN1CHRM1USP30GSK3BDYRK1A | |
| SCHEMBL19998604 | 0.74 | ERN1 (0.56) | ERN1CHRM1USP30GSK3BDYRK1A | |
| SCHEMBL17809509 | 0.73 | WDR5 (0.56) | — | |
| SCHEMBL17785811 | 0.72 | ERN1 (0.46) | ERN1CHRM1GSK3BDYRK1A | |
| SCHEMBL17809627 | 0.72 | CREBBP (0.42) | ERN1CYP11B2USP30GSK3BDYRK1A | |
| SCHEMBL17809502 | 0.72 | CREBBP (0.44) | CYP11B2USP30GSK3BDYRK1A | |
| SCHEMBL12363773 | 0.72 | CYP11B2 (0.35) | CYP11B2 | |
| SCHEMBL17809710 | 0.70 | ERN1 (0.52) | ERN1CHRM1USP30GSK3BDYRK1A | |
| SCHEMBL18259536 | 0.70 | ERN1 (0.51) | ERN1CHRM1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | ERN1 861/4885CYP11B2 1605/4885CHRM1 1855/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | ERN1 861/4885CYP11B2 1605/4885CHRM1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.